164 related articles for article (PubMed ID: 26983223)
1. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
[TBL] [Abstract][Full Text] [Related]
2. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines].
Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y
Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610
[TBL] [Abstract][Full Text] [Related]
3. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
Shang HC; Zhang BL; Li YP
Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
[TBL] [Abstract][Full Text] [Related]
5. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
6. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
7. [Research on distribution of patents' holders for Chinese herbal compounds in treating cardiovascular and cerebrovascular based on cluster analysis].
YANG XJ; XIAO SY
Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3682-6. PubMed ID: 26983221
[TBL] [Abstract][Full Text] [Related]
8. [Post-marketing reevaluation for potential quality risk and quality control in clinical application of traditional Chinese medicines].
Li HJ; He LY; Liu BY
Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2461-3. PubMed ID: 26591543
[TBL] [Abstract][Full Text] [Related]
9. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm.
Liao X; Xie YM; Robinson N; Wang YY
Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
11. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
Yang W; Xie Y; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
[TBL] [Abstract][Full Text] [Related]
12. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
Yan BH; Peng C; Xie YM; Wang YY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
[TBL] [Abstract][Full Text] [Related]
13. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
Xie YM; Wang X; Wang N; Chang YP
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
[TBL] [Abstract][Full Text] [Related]
14. [Post-marketing clinical study of traditional Chinese medicine--lessons learned from comprehensive evaluation of Fufang Zaoren capsule].
Qing S; Gao L; Zhang L; Jia JP; Liu XM; Ji SL; Yang XH
Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3790-4. PubMed ID: 24494575
[TBL] [Abstract][Full Text] [Related]
15. [Core elements of safety monitoring report of medicines(Chinese patent medicines)].
Wang GQ; Liao X; Xie YM
Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4483-4487. PubMed ID: 28936827
[TBL] [Abstract][Full Text] [Related]
16. [Dynamic monitoring risk of anti-hepatoma new drug development].
Zhang J; Fan W; Li HF; Man SL; Liu Z; Gao WY
Zhongguo Zhong Yao Za Zhi; 2014 Oct; 39(20):4050-3. PubMed ID: 25751961
[TBL] [Abstract][Full Text] [Related]
17. [Significance of re-evaluation and development of Chinese herbal drugs].
Gao Y; Ma Z; Zhang B
Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(1):1-4. PubMed ID: 22741451
[TBL] [Abstract][Full Text] [Related]
18. [Survey on Xiaoke pill treating diabetes mellitus in small cities' Chinese medicine hospital for post-marketing surveillance].
Xie Y; Zhao Y; Liu H; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2859-61. PubMed ID: 22292385
[TBL] [Abstract][Full Text] [Related]
19. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
Zhang W; Xie YM; Yu WY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
